menu
    • menu
    [{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Centers for Disease Control and Prevention","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Nitroxoline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Asieris Pharmaceuticals \/ Centers for Disease Control and Prevention","highestDevelopmentStatusID":"6","companyTruncated":"Asieris Pharmaceuticals \/ Centers for Disease Control and Prevention"}]

    Find Clinical Drug Pipeline Developments & Deals for Nitroxoline

    Menu

    Nitroxoline

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Asieris Pharmaceuticals

    China arrow
    BePharma
    Not Confirmed

    Asieris Pharmaceuticals

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nitroxoline

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase I

    Sponsor : Centers for Disease Control and Prevention

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Asieris, CDC Sign Agreement for APL-1202 Under Expanded Access Program

    Details : Asieris has entered into an agreement to collaborate with the CDC in the US on APL-1202 (nitroxoline), It is being investigated for the treatment of FLA infections.

    Product Name : APL-1202

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    January 06, 2025

    Lead Product(s) : Nitroxoline

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Sponsor : Centers for Disease Control and Prevention

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth